Burlington Stores, Inc. vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines Burlington Stores, Inc. and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Burlington Stores, Inc. on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Burlington Stores, Inc. and Cardinal Health, Inc. is widest.

On the headline numbers, Burlington Stores, Inc. reports annual revenue of $11.6B against $254.2B for Cardinal Health, Inc., while their respective market capitalizations stand at $16.8B and $56.0B. Both Burlington Stores, Inc. and Cardinal Health, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Burlington Stores, Inc.: Burlington, known as Burlington Coat Factory until 2013, is one of the three big U.S. off-price chains alongside TJX and Ross Stores. Shoppers come for branded women's, men's and children's clothing, shoes, accessories, baby gear in the Baby Depot department, beauty, toys and home decor, all priced below department stores. Stock changes constantly because it is bought from whatever surplus brands and retailers have, so the store works as a treasure hunt: an item on the rack this week may be gone the next. Coats remain a signature category inside a year-round assortment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Burlington Stores, Inc. and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Burlington Stores, Inc. and Cardinal Health, Inc..

Burlington Stores, Inc. business model: Burlington makes nearly all of its money from merchandise sold in its stores. Net sales were $11.55 billion of its $11.57 billion fiscal 2025 total revenue; the remaining $17 million of other revenue comes from sources such as rental income and service fees. Its merchants buy branded goods when manufacturers or other retailers have excess stock, cancelled orders or closeouts, which lets Burlington price items below department stores. Some buys are held back as packaway inventory and released to stores later in the season or the following year. Under the Burlington 2.0 plan introduced by CEO Michael O'Sullivan, stores carry less inventory and buyers keep more money open to purchase closer to the selling season, so they can react to what is selling. The company has sold only through stores since it announced the end of its e-commerce business in March 2020, judging the small online operation unprofitable for low-priced off-price merchandise.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Burlington Stores, Inc. stack up against those of Cardinal Health, Inc..

Burlington Stores, Inc. competitive advantage: Burlington's edge is cost and flexibility. Because it does not commit to full seasonal assortments months ahead, its buyers can take excess branded inventory when it becomes available and price it below department stores. Selling only in stores, with no e-commerce since March 2020, keeps parcel shipping and online returns out of the cost base. Its real estate approach adds a further advantage: it has repeatedly taken over leases from bankrupt chains, including 62 former Bed Bath & Beyond sites in 2023 and 45 Joann sites in 2025, which gives it ready-built stores in established shopping centers.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Future prospects matter as much as current results. The growth strategies below explain how Burlington Stores, Inc. and Cardinal Health, Inc. each plan to expand from here.

Burlington Stores, Inc. growth strategy: Burlington grows mainly by opening stores. It added 178 gross and 149 net new stores in the 12 months to August 1, 2026, and plans about 115 net openings in fiscal 2026. New stores use a smaller prototype of about 25,000 square feet instead of the very large boxes of the Coat Factory era, which lowers rent and labor per store. Many sites come from retailer bankruptcies: Burlington took on 62 Bed Bath & Beyond leases in 2023 and 45 Joann leases in 2025, and the Joann sites feed a large share of its 2026 openings. Inside existing stores, the Burlington 2.0 plan focuses on leaner inventory, faster turns and buying closer to need.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

A closer look at the financial trajectory of Burlington Stores, Inc. and Cardinal Health, Inc. rounds out the comparison.

Burlington Stores, Inc.: Burlington's total revenue roughly doubled from $5.59 billion in fiscal 2016 to $11.57 billion in fiscal 2025. The exception was fiscal 2020, when pandemic store closures cut revenue to $5.76 billion and produced a $216.5 million net loss. Profit has since grown faster than sales: net income went from $230.1 million in fiscal 2022 to $339.6 million, $503.6 million and $610.2 million over the next three years. Heavy store investment limits free cash flow, which was about $172 million in fiscal 2025 after roughly $1.06 billion of capital spending. In the second quarter of fiscal 2026 (to August 1, 2026), total sales rose 11 percent to $2.998 billion and net income was $184 million, including a $41 million after-tax benefit from tariff refunds. The company raised its full-year adjusted EPS guidance to $11.77 to $11.97.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.